Minerva Medica 2021 Jan 26

DOI: 10.23736/S0026-4806.21.07266-9

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Synergy across the drugs approved for the treatment of asthma

Paola ROGLIANI ^{1, 2} ✉, Beatrice L. RITONDO ¹, Francesco CAVALLI ¹, Federica GIORGINO ², Andrea GIROLAMI ², Gloria PANE ², Gabriella PEZZUTO ², Bartolomeo ZERILLO ², Ermanno PUXEDDU ^{1, 2}, Josuel ORA ²

¹ Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy; ² Division of Respiratory Medicine, University Hospital Policlinico Tor Vergata, Rome, Italy

INTRODUCTION: Inhaled corticosteroids are the cornerstone for the treatment of stable asthma, however, when disease severity increases, escalating therapy to combinations of drugs acting on distinct signalling pathways is required. It is advantageous to providing evidence of a synergistic interaction across drug combinations, as it allows optimizing bronchodilation while lowering the dose of single agents. In the respiratory pharmacology field, two statistical models are accepted as gold standard to characterize drug interactions, namely the Bliss Independence criterion and the Unified Theory. In this review, pharmacological interactions across drugs approved for the treatment of asthma have been systematically assessed.
EVIDENCE ACQUISITION: A comprehensive literature search was performed in MEDLINE for studies that used a validated pharmacological method for assessing drug interaction. The results were extracted and reported via qualitative synthesis.
EVIDENCE SYNTHESIS: Overall, 45 studies were identified from literature search and 5 met the inclusion criteria. Current evidence coming from ex vivo models of asthma indicates that drug combinations modulating bronchial contractility induce a synergistic bronchorelaxant effect. In murine models of lung inflammation, the combination between inhaled corticosteroids and β2- adrenoceptor agonists synergistically improve lung function and the inflammatory profile.
CONCLUSIONS: There is still limited knowledge regarding the mechanistic basis underlying pharmacological interactions across drugs approved for asthma. The synergism elicited by combined agents is an effect of class. Specifically designed clinical trials are needed to confirm the results coming from preclinical evidence, but also to establish the minimal dose for combined agents to induce a synergistic interaction and maximize bronchodilation.

KEY WORDS: Asthma; Bronchodilators; ICS; LABA; Synergy